Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 51 of 63 15. INDEX OF TABLES, LISTINGS, AND FIGURES The lists of tables, listings, and figures will be provided in a separate document. DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 52 of 63 16. APPENDICES Appendix 1 – Study Event Schedule: Stage 1 Appendix 2 – Study Event Schedule: Stage 2 Appendix 3 – Modified RANO Criteria for Response Assessment Appendix 4 – Karnofsky Performance Scale Appendix 5 – RECIST Criteria for Response Assessment (Version 1.1) Appendix 6 – Overall Response Assessment at Visit (RECIST) Appendix 7 – Assignment of Best Overall Response When Confirmation of CR/PR Is Required DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Statistical Analysis Plan Page 53 of 63 17. APPENDIX 1 - STUDY EVENT SCHEDULE: STAGE 1 DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 54 of 63 DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 55 of 63 DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 56 of 63 18. APPENDIX 2 - STUDY EVENT SCHEDULE: STAGE 2 DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 57 of 63 DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 58 of 63 DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Statistical Analysis Plan Page 59 of 63 19. APPENDIX 3 – KARNOFSKY PERFORMANCE SCALE From: Oxford Textbook of Palliative Medicine, Oxford University Press. 1993; 109 100 Normal, no complaints; no evidence of disease 90 Able to carry on normal activity; minor signs or symptoms of disease 80 Normal activity with effort; some signs or symptoms of disease 70 Cares for self; unable to carry on normal activity or do active work 60 Requires occasional assistance, but is able to care for most personal needs 50 Requires considerable assistance and frequent medical care 40 Disabled; requires special care and assistance 30 Severely disabled; hospitalization is indicated, although death is not imminent 20 Very sick; hospitalization necessary; active support treatment is necessary 10 Moribund; fatal processes progressing rapidly 0 Dead DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 60 of 63 20. APPENDIX 4 – MODIFIED RANO CRITERIA FOR RESPONSE ASSESSMENT DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 61 of 63 21. APPENDIX 5 – RECIST CRITERIA FOR RESPONSE ASSESSMENT (VERSION 1.1) DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 62 of 63 22. APPENDIX 6 – OVERALL RESPONSE ASSESSMENT AT VISIT (RECIST) From Eisenhauer 2009 Overall Response for Patients with Target Lesions Target Lesions Non-Target Lesions New Lesions Overall Response CR CR No CR CR Non-CR/Non- PR No PR CR Not evaluated No PR PR Non-PD or not all evaluated No PR SD Non-PD or not all evaluated No SD Not all evaluated Non- PD No NE PD Any Yes or No PD Any PD Yes or No PD Any Any Yes PD NE=Not evaluable Overall Response for Patients with Non-Target Disease Only Non-Target Lesions New Lesions Overall Response CR No CR Non-CR/Non- PD No Non-CR/Non- PD Not all evaluated No NE Uniquivocal PD Yes or No PD Any Yes PD DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 63 of 63 23. APPENDIX 7 – ASSIGNMENT OF BEST OVERALL RESPONSE WHEN CONFIR MATION OF CR/PR IS REQUIRED From Eisenhauer 2009 Overall Response First Time Point Overall Response Subsequent Time Point BEST Overall Response CR CR CR CR PR SD, PD, or PRa CR SD SD provided minimum criteria for SD duration met, otherwise PD CR PD SD provided minimum criteria for SD duration met, otherwise PD CR NE SD provided minimum criteria for SD duration met, otherwise NE PR CR PR PR PR PR PR SD SD PR PD SD provided minimum criteria for SD duration met, otherwise PD PR NE SD provided minimum criteria for SD duration met, otherwise NE NE NE NE a – If a CR is truly met at first time point, then any disease seen at a subsequent time point,even disease meeting PR criteria relative to baseline, makes the disease PD at that point (since disease must have appeared after CR). Best response would depend on whether minimum duration for SD was met. However, sometimes ‘CR’ may be claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR. DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3